Update on Immune Checkpoint Inhibition for Cervical Cancer

H&O What is it about the biology of cervical cancer that makes it an attractive target for immune checkpoint inhibition? LD More than 98% of cases […]

Management of Low-Grade Serous Carcinoma of the Ovary

H&O How common is low-grade serous ovarian cancer? RG Low-grade serous ovarian cancer accounts for fewer than 10% of new cases of epithelial ovarian cancer, so […]

The Use of Antibody-Drug Conjugates in Gynecologic Cancers

H&O What makes antibody-drug conjugates (ADCs) particularly promising for treating gynecologic cancers in comparison with traditional chemotherapy? JL ADCs are a form of targeted chemotherapy. When […]

Advances in Uterine Serous Carcinoma and Uterine Carcinosarcoma

H&O Uterine serous carcinoma and uterine carcinosarcoma have distinct molecular and histologic profiles. How do these differences affect prognosis? GF Uterine serous carcinoma and uterine carcinosarcoma […]